Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04502394
What this trial is testing

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Who this might be right for
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Kartos Therapeutics, Inc. 84
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06652139
What this trial is testing

Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive

Who this might be right for
Diffuse Large B Cell Lymphoma
Ruijin Hospital 82
Early research (Phase 1)Study completedNCT03955783
What this trial is testing

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Who this might be right for
Diffuse Large B-cell LymphomaAcute Myeloid LeukemiaNon-Hodgkin's Lymphoma
Sanjay Mohan 78
Early research (Phase 1)UnknownNCT04684472
What this trial is testing

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory Leukemia
Liqun Zou 18
Early research (Phase 1)Study completedNCT03886831
What this trial is testing

PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Who this might be right for
Relapsed/Refractory Advanced Solid TumorsRelapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Myelodysplasia+5 more
Prelude Therapeutics Incorporated 232
Testing effectiveness (Phase 2)Study completedNCT03992339
What this trial is testing

Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Antengene Corporation 60
Testing effectiveness (Phase 2)Study completedNCT03484702
What this trial is testing

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 113
Very early researchNot Yet RecruitingNCT04609241
What this trial is testing

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed and/or Refractory Acute Lymphoblastic LeukemiaRelapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
Zhejiang University 72
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07122609
What this trial is testing

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed and Refractory DLBCL
Ruijin Hospital 22
Testing effectiveness (Phase 2)Study completedNCT01381692
What this trial is testing

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Who this might be right for
Recurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma+8 more
National Cancer Institute (NCI) 9
Early research (Phase 1)Study completedNCT02631044
What this trial is testing

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Who this might be right for
Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+2 more
Juno Therapeutics, a Subsidiary of Celgene 387
Testing effectiveness (Phase 2)WithdrawnNCT05929716
What this trial is testing

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Large B-cell LymphomaB-cell Lymphoma
M.D. Anderson Cancer Center
Early research (Phase 1)Ended earlyNCT05515406
What this trial is testing

Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Who this might be right for
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Ono Pharmaceutical Co., Ltd. 9
Testing effectiveness (Phase 2)WithdrawnNCT06005649
What this trial is testing

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-hodgkin Lymphoma
Juventas Cell Therapy Ltd.
Early research (Phase 1)Study completedNCT05359211
What this trial is testing

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+6 more
Fred Hutchinson Cancer Center 27
Early research (Phase 1)Study completedNCT01897012
What this trial is testing

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Who this might be right for
MYC PositiveRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt Lymphoma+14 more
National Cancer Institute (NCI) 26
Early research (Phase 1)Active Not RecruitingNCT04684563
What this trial is testing

HuCART19-IL18 in CD19+ Cancers

Who this might be right for
Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia
University of Pennsylvania 72
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Testing effectiveness (Phase 2)Study completedNCT02086175
What this trial is testing

Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Dana-Farber Cancer Institute 25
Next Page